Dr. Barry D. Bertolet, MD

Medicare patients and services

Medicare patients, 2024

2,069

Services billed

12,102

Patients’ average age

75

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 29 companies reported 217 payments worth $80,075 in total to this clinician.

What the payments were for

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Mississippi →

Industry-funded research

Named as a principal investigator on 16 industry-funded studies in 2025, from 8 companies. The companies reported $1,227,874 in research payments for these studies, mostly to the institutions running them.

• SPYRAL AFFIRM
  Medtronic, Inc.
• A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT)
  Novartis Pharmaceuticals Corporation
• A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fi…
  Janssen Research & Development, LLC
• ALLEVIATE-HF
  Medtronic, Inc.
• A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic C…
  E.r. Squibb & Sons, L.l.c.
• Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT)
  Novartis Pharmaceuticals Corporation
• Drug-Eluting Registry: Real-World Treatment of Lesions in the Peripheral Vasculature
  Boston Scientific Corporation · Recruiting · NCT04674969
• Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)
  Alnylam Pharmaceuticals Inc.
• Prospective, Multi-center, Single-arm Study of the Shockwave Medical Peripheral Intravascular Lithotripsy (IVL) System for Treatment of Calcified Peripheral Arterial Disease (PAD) in Below-the-Knee (BTK) Arteries
  Shockwave Medical, Inc
• A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE (LIBREXIA-STROK)
  Janssen Research & Development, LLC

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Cardiology clinicians in Tupelo

• Joseph C. Adams, MD
• Benjamin D. Blossom, M.D.
• Michael T. Boler JR., D.O.
• William B. Calhoun, MD
• William S. Carroll, MD
• John M. Estess JR., MD
• Jack B. Foster JR., MD
• Douglas L. Hill, MD